Drugs, CervicalCheck and government inequity
Of course cancer patients want to access the new, ‘wonder drugs’, but the money would have to be taken from other healthcare services
The government made the decision to reimburse experimental drugs for women affected by the CervicalCheck debacle last May.
It bypassed the approvals process that all drugs usually go through - namely a cost-effectiveness assessment by the National Centre for Pharmacoeconomics (NCPE).
It was an unprecedented move - and a very ill-advised one.
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
Private rental sector remains strong despite Covid-19
Demand continues to outstrip supply in both residential and PRS markets, while developers adapt new build designs to take the pandemic into account
How the programme for government will shape housing
Several strategic changes offer an opportunity for positive reform of planning and development
Comment: US must defuse Covid-19’s ticking time bomb of debt
The United States cannot defeat the pandemic like a military foe but it can learn from looking back at its post-war economic recovery